by David Kent | Mar 16, 2015
> The last 15 years of stem cell research have been full of hope and promises – some of it delivered upon, most of it not quite there yet, and some of it miserably failed. I guess that is to be expected in a highly experimental area of medicine, but one of the most...
by James Smith | Dec 11, 2014
. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York...
by Mark Curtis | Oct 17, 2013
. Welcome to the first Regenerative Medicine Deal Review, an overview of recent licensing, partnering, and financing activity all exclusively in the regenerative medicine and cell therapy industries. Like my first post ‘Update from the Clinic’, this piece is intended...
by Angela C. H. McDonald | Jun 14, 2013
. Shortly after I started my PhD in 2009, Time magazine profiled a Harvard Stem Cell Institute researcher, Doug Melton, who dedicated his research program to understanding the development and biology of pancreatic beta cells following the diagnosis of his children...
by Lisa Willemse | Jun 29, 2012
With contributions from Michael Rudnicki. If you’re following recent announcements in the field, then you may know about the study published this week in Diabetes that details the use of human embryonic stem cells (hESCs) to reverse diabetes type 1 in a mouse...
Comments